• Have one of the following solid tumor cancers:

‣ Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer

⁃ Cohort A2/B1/B2: urothelial carcinoma

⁃ Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer

• Prior Systemic Therapy Criteria:

‣ Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies

⁃ Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.

• Prior enfortumab vedotin specific requirements:

‣ Cohorts A1/A2/C: prior treatment with enfortumab vedotin is allowed, but not required

⁃ Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting

⁃ Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.

• Measurability of disease

‣ Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)

⁃ Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations